Profile data is unavailable for this security.
About the company
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
- Revenue in USD (TTM)74.02m
- Net income in USD-30.75m
- Incorporated2010
- Employees132.00
- LocationOptiNose Inc777 Township Line Road, Suite 300YARDLEY 19067United StatesUSA
- Phone+1 (267) 364-3500
- Fax+1 (302) 636-5454
- Websitehttps://www.optinose.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomea Fusion Inc | 0.00 | -127.27m | 148.81m | 110.00 | -- | 1.10 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 149.00m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 150.00m | 10.00 | -- | 0.7894 | -- | 75.00 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| ProQR Therapeutics NV | 14.57m | -28.99m | 150.51m | 157.00 | -- | 4.14 | -- | 10.33 | -0.3571 | -0.3571 | 0.1794 | 0.4464 | 0.0957 | -- | -- | 92,783.29 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 151.66m | 46.00 | -- | 1.28 | -- | 9.35 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 151.83m | 107.00 | -- | 0.6294 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| I-Mab ADR | 3.81m | -202.23m | 152.06m | 220.00 | -- | 0.64 | -- | 39.87 | -2.43 | -2.43 | 0.0458 | 2.94 | 0.0083 | -- | -- | 17,337.64 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 152.56m | 121.00 | -- | 0.8369 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| OptiNose Inc | 74.02m | -30.75m | 153.53m | 132.00 | -- | -- | -- | 2.07 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Atossa Therapeutics Inc | 0.00 | -29.69m | 157.20m | 10.00 | -- | 1.83 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 157.37m | 100.00 | -- | 5.67 | -- | 1.87 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 157.41m | 51.00 | -- | 0.6007 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 157.69m | 159.00 | -- | 3.88 | -- | 1.75 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Mediwound Ltd | 19.85m | -12.75m | 158.19m | 100.00 | -- | 6.97 | -- | 7.97 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| CervoMed Inc | 9.49m | -593.84k | 158.39m | 8.00 | 9.72 | 22.19 | -- | 16.69 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Data as of Jun 11 2024. Currency figures normalised to OptiNose Inc's reporting currency: US Dollar USD
49.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 14.57m | 12.93% |
| Great Point Partners LLCas of 31 Mar 2024 | 8.79m | 7.80% |
| Rosalind Advisors, Inc.as of 10 May 2024 | 7.55m | 6.70% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.10m | 3.64% |
| Bleichroeder LPas of 31 Mar 2024 | 4.05m | 3.59% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.93m | 3.49% |
| Kingdon Capital Management LLCas of 31 Mar 2024 | 3.90m | 3.46% |
| Velan Capital Investment Management LPas of 31 Mar 2024 | 3.00m | 2.66% |
| Massachusetts Financial Services Co.as of 31 Mar 2024 | 2.84m | 2.52% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 2.47m | 2.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
